GSK resolves patent lawsuit against Pfizer over RSV vaccines
By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...
European Commission approves Pfizer's RSV vaccine for adults at increased risk of disease
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
Pfizer (NYSE:PFE) Expands RSV Vaccine Use In Europe Amid 3% Share Price Dip
Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...
GSK, Pfizer Agree to End Patent Lawsuit Over Rival RSV Vaccines
GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...
Fierce Pharma1d
GSK, Pfizer resolve RSV patent feud amid vaccine market uncertainty
As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...
EconoTimes1d
GSK and Pfizer Drop RSV Vaccine Patent Lawsuit
GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...
Pfizer (NYSE:PFE) Involved In Lawsuit Over US$45 Per Share Cerevel Acquisition
In recent developments, a class action lawsuit was filed against Cerevel Therapeutics, Bain Capital Investors, and Pfizer ...
STAT1d
Pharmalittle: We’re reading about FDA scrambling for workers, Pfizer CEO pay and more
Just hours after thousands of U.S. Food and Drug Administration employees were shown the door, Barclay Butler, the agency’s ...
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna
Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...
Medscape12d
Bivalent RSV Vaccine Shows Sustained Efficacy and Safety Through Two Seasons in Older Adults
The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...
Pfizer, GSK settle patent lawsuit over RSV vaccines
Pfizer (NYSE:PFE) and GSK (NYSE:GSK) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, ...
U.S. News & World Report2d
GSK Resolves Patent Lawsuit Against Pfizer Over RSV Vaccines
(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...